Related by context. All words. (Click for frequent words.) 62 randomized controlled Phase 61 multicenter randomized controlled 61 CIMZIA TM certolizumab pegol 61 Phase III randomized controlled 61 Phase IIIb study 61 phase IIa clinical 61 HCV RESPOND 2 61 multicenter Phase II 61 phase IIIb 60 mg/m2 dose 60 MGd 60 phase IIb study 60 brivaracetam 60 dose cohort 60 Phase IIb clinical trials 60 BCIRG 60 multicenter phase 60 Amrubicin 59 multicenter Phase 59 sorafenib Nexavar 59 treatment naive genotype 59 prospective observational 59 Phase Ib clinical 59 bendamustine 59 phase IIb trial 59 standard chemotherapy regimen 59 sunitinib malate 58 multicentre 58 double blinded placebo 58 refractory CLL 58 CLL SLL 58 HCV SPRINT 58 dose escalation Phase 58 dose escalation clinical 58 CIMZIA TM 58 Phase IIIb clinical 58 Phase IIIb 58 ADVANCE PD 58 phase IIb clinical 58 colesevelam HCl 58 placebo controlled Phase 58 chemoradiotherapy 58 Phase 2b study 58 pain palliation 58 #mg dosing group 58 randomized multicenter trial 58 Phase IIB 58 relapsed MM 58 RSD# oral 58 BR.# 58 desvenlafaxine succinate 57 fosbretabulin 57 placebo controlled Phase III 57 phase Ib 57 ZACTIMA 57 elotuzumab 57 dosing cohort 57 PEG IFN 57 ascending dose 57 CLARITY study 57 salmeterol fluticasone 57 GEM OS1 57 mCi kg 57 recurrent GBM 57 registrational 57 AIR CF1 57 Phase Ib study 57 RE LY ® 57 Pegasys ® 57 ABSORB trial 57 BEACOPP 57 patients undergoing CABG 57 relapsed refractory multiple myeloma 57 leukemia AML 57 CALGB # [002] 57 mcg QD 57 prospective randomized multicenter 57 null responder HCV 57 adjuvant tamoxifen 57 PRECiSE 57 APTIVUS 57 doxorubicin docetaxel 57 Phase IIa trial 57 concurrent chemoradiation 57 prospective nonrandomized 57 CIMZIA ™ 57 eosinophilic asthma 57 histologically confirmed 57 prucalopride 57 undetectable HBV DNA 57 Phase #/#a 57 inhibitor RG# 57 randomized multicenter 57 tipranavir r 57 NSABP B 56 intermittent dosing 56 #mg QD [001] 56 CHOP chemotherapy 56 multicentre randomized 56 multicenter Phase III 56 irbesartan 56 double blinded randomized 56 evaluating REVLIMID 56 recurrent glioblastoma multiforme 56 4mg/kg 56 Dacogen injection 56 Phase 1b clinical 56 Phase III psoriasis 56 active comparator 56 icatibant 56 pharmacokinetic PK study 56 Doxil ® 56 dose escalation phase 56 everolimus eluting stents 56 AEGR 56 Phase III randomized 56 AIR CF2 56 GOUT 56 biliary tract cancer 56 dose escalation trial 56 evaluable subjects 56 prospective multicenter randomized 56 comparator arm 56 ENGAGE AF TIMI 56 Phase 2a trial 56 HSCT 56 multicenter prospective 56 Diabetic Macular Edema DME 56 EOquin TM 56 multicenter randomized clinical 56 CANCIDAS 56 pegylated interferon alfa 2b 56 prospective multicenter study 56 randomized Phase IIb 56 viral kinetics 56 nab paclitaxel 56 TORISEL 56 Phase #b/#a 56 IFN alfa 56 oral ridaforolimus 56 relapsing multiple sclerosis 56 octreotide LAR 56 Fludara 56 certolizumab 56 prospective multicenter 56 Elitek 56 FAME Study 56 APTIVUS r 56 azacitidine 56 multicenter 56 GSK# [001] 56 NATRECOR R 56 STRIDE PD 55 phase IIa 55 mg kg dose 55 HER2 positive metastatic breast 55 postoperative chemotherapy 55 randomized blinded 55 CHAMPION PCI 55 registrational trial 55 unfractionated heparin UFH 55 Alzhemed TM 55 APPRAISE 55 dose dose escalation 55 Betaferon ® 55 BRIM2 55 TMC# C# 55 Feasibility Trial 55 chemoradiation therapy 55 phase Ib clinical 55 recurrent malignant glioma 55 moderately emetogenic 55 Phase 2b clinical trials 55 Cloretazine 55 fondaparinux 55 symptomatic BPH 55 HORIZONS AMI trial 55 dacarbazine chemotherapy 55 evaluating tivozanib 55 genotype 1a 55 postintervention 55 teriflunomide 55 Phase 2b trial 55 dose cohorts 55 Phase 1b clinical trials 55 retrospective cohort study 55 RE LY 55 satraplatin Phase 55 gemcitabine cisplatin 55 Xelox 55 Acute Ischemic Stroke 55 forodesine 55 Pemetrexed 55 pegylated liposomal doxorubicin 55 KRAS mutations occur 55 placebo controlled clinical 55 MEND CABG 55 Traficet EN 55 IFN α 55 liver resection 55 Phase #b/#a trial 55 metastatic CRC 55 Zenvia Phase III 55 Phase IIa trials 55 prospective randomized placebo 55 rapid virologic response 55 liposomal formulation 55 TMC# r 55 bevirimat Study 55 thorough QT 55 blinded randomized placebo controlled 55 multicenter randomized 55 Zenvia ™ 55 blind multicenter 55 lanthanum carbonate 55 #mg BID [001] 55 Group RTOG 55 metastatic malignant 55 Bezielle 55 radical cystectomy 55 insulin detemir 55 ACTEMRA TM 55 FOSRENOL R 55 EURIDIS 55 budesonide foam 55 Fibrillex TM 55 estramustine 55 randomized #:#:# 54 Phase Ib II 54 glatiramer acetate 54 ExTRACT TIMI 54 clinical pharmacology studies 54 pharmacokinetic PK 54 dabigatran etexilate 54 alvimopan 54 briakinumab 54 fenofibric acid 54 dose titration 54 mcg BID 54 RG# [001] 54 darinaparsin 54 mCRC patients 54 CCyR 54 dosing cohorts 54 APEX AMI trial 54 allogeneic HSCT 54 #mg dosing 54 diabetic neuropathic pain 54 PEGINTRON TM 54 PD LID 54 dose escalation study 54 MAGE A3 ASCI 54 Phase 1b trial 54 multicentre prospective 54 pitavastatin 54 anti arrhythmic drug 54 ritonavir boosted 54 evaluable patients 54 liposomal doxorubicin 54 #mg/day [001] 54 SUCCEED trial 54 subanalysis 54 adjuvant cisplatin 54 docetaxel chemotherapy 54 pharmacodynamic PD 54 REVIVE Diabetes 54 ARCOXIA 54 FOLPI 54 ongoing Phase 1b 54 multicenter randomized placebo controlled 54 cell lymphoma CTCL 54 IBS C 54 adalimumab Humira 54 clevidipine 54 TEMODAL 54 stage IIIB 54 Phase 2a 54 Carotid Revascularization Endarterectomy vs. 54 RTOG 54 Myelodysplastic syndromes MDS 54 MoxDuo TM IR 54 BRIM3 54 #mg BID [003] 54 CRp 54 tanespimycin 54 Ixempra 54 Phase 2a clinical 54 rufinamide 54 Ranolazine 54 CLL8 54 Engerix B 54 Cimzia TM 54 DAPT 54 REVLIMID lenalidomide 54 VNP#M 54 PROMACTA 54 treatment naïve genotype 54 rFVIIa 54 ENDEAVOR IV 54 Arsenic trioxide 54 telaprevir dosing 54 multicentre study 54 unresectable HCC 54 metastatic HRPC 54 neoadjuvant treatment 54 PRoFESS 54 pegylated interferon alpha 54 crizotinib PF # 54 Natalizumab 54 ECASS 54 neratinib 54 posaconazole 54 hepatic metastases 54 sorafenib tablets 54 Screening Trial 54 Folfox 54 pouchitis 54 preoperative chemotherapy 54 placebo dexamethasone 54 peginterferon alfa 2a #KD 54 administered subcutaneously 54 Betaferon R 54 antiretroviral naïve 54 Phase IIb clinical 54 retrospective observational study 54 Diabetic Macular Edema 54 LEXIVA r 54 pertuzumab 54 SNT MC# 54 tamsulosin 54 Tarceva TM 53 vapreotide acetate 53 interferon ribavirin 53 IV NSCLC 53 8mg/kg 53 solifenacin 53 RAPTIVA 53 EINSTEIN DVT 53 pomalidomide 53 abiraterone acetate 53 multicentre randomized double 53 trabectedin 53 lumbar spine BMD 53 vandetanib 53 primary hypercholesterolemia 53 Aptivus ® 53 AIR CF3 53 oral deforolimus 53 achieved ACR# 53 receiving VICTRELIS 53 TYGACIL 53 APEX PD 53 PSMA ADC 53 intravenous dosing 53 phase IIb 53 tocilizumab 53 PegIFN RBV 53 HBeAg negative patients 53 LUX Lung 53 acute coronary syndromes ACS 53 Pegasys plus Copegus 53 docetaxel Taxotere R 53 eszopiclone 53 Randomized Evaluation 53 eribulin mesylate 53 Phase Ib 53 randomized Phase 2b 53 riociguat 53 AIM HIGH 53 mg/m2 cohort 53 refractory chronic lymphocytic 53 paclitaxel Taxol R 53 randomized Phase III 53 superficial bladder cancer 53 INCB# [001] 53 advanced hepatocellular carcinoma 53 TAXUS ATLAS 53 daily subcutaneous injections 53 R# #mg BID 53 blind randomized 53 galiximab 53 ORENCIA ® 53 mg QD 53 multicenter study 53 AGILECT R 53 μg dose 53 gemcitabine Gemzar ® 53 TACE 53 somatostatin analog 53 ancrod 53 metastatic hormone refractory 53 metastatic renal cell carcinoma 53 NOXAFIL 53 Phase 1a clinical 53 PHX# 53 elective PCI 53 IIa trial 53 endoscopic remission 53 COPAXONE R 53 Cethrin 53 definite stent thrombosis 53 mg TID 53 Myocardial Infarction Study 53 AGILECT ® 53 lenalidomide dexamethasone 53 relapsed CLL 53 ACZ# 53 RhuDex R 53 FOLFOX4 53 dose escalation 53 multicenter clinical 53 Phase 1b 53 IRESSA 53 tapentadol ER 53 titration phase 53 alfa 2a 53 achieved statistical significance 53 Phase IIb trials 53 piperacillin tazobactam 53 QD dosing 53 Afatinib 53 LUMINATE 53 coinfected patients 53 oxycodone CR 53 prospective multicentre 53 underwent resection 53 platelet inhibitor 53 docetaxel Taxotere ® 53 amrubicin 53 MIRAPEX 53 multicenter placebo controlled 53 lexidronam injection 53 allogeneic hematopoietic stem cell 53 INCB# [003] 53 RECORD1 53 Phase #b/#a clinical 53 CIMZIA R 53 dosage regimens 53 intratumoural 53 substudy 53 bosentan 53 prospective randomized controlled 53 hENT1 53 phase IIb III 53 GAMMAGARD 53 lenalidomide Revlimid R 53 topotecan 53 eptifibatide 53 reslizumab 53 refractory metastatic colorectal cancer 53 MIST II 53 patients evaluable 53 azilsartan medoxomil 53 stage IIIb IV 53 remission induction 53 Mitoxantrone 53 prospectively randomized 53 eprotirome 53 Allovectin 7 ® 53 Placebo Controlled Trial 53 REMINYL ® 53 CR CRu 53 hepatic resection 53 Thrombolysis 53 INSPIRE Trial Phase III 53 Stenting Trial CREST 53 heFH 53 sunitinib 53 ofatumumab 52 diagnosed GBM 52 placebo controlled randomized 52 low dose cytarabine 52 #mg/m# [001] 52 ezetimibe simvastatin 52 lomitapide 52 label multicenter 52 Multicenter 52 ug kg 52 neoadjuvant 52 multicenter multinational 52 viral kinetic 52 Phase III VISTA 52 subcutaneous methylnaltrexone 52 myelodysplastic syndromes MDS 52 tirofiban 52 Phase III placebo controlled 52 liposome injection 52 EVEREST II 52 Aryplase 52 randomized Phase 52 NICE SUGAR 52 Augment Injectable 52 CALGB 52 candesartan cilexetil 52 DOXIL 52 intravenous bolus 52 Phase IIa clinical 52 placebo controlled studies 52 trials RCTs 52 underwent CABG 52 zalutumumab 52 palifermin 52 TG MV 52 zonisamide SR 52 TRANSFORMS 52 SCH # 52 nonmetastatic prostate cancer 52 #mg/day [002] 52 fostamatinib 52 imetelstat 52 IV bolus 52 heavily pretreated 52 alkylating agent 52 ipsilateral stroke 52 Tolvaptan 52 mg administered orally 52 BoNTA 52 FOLOTYN ® 52 ASCT 52 XELOX 52 interferon gamma 1b 52 postmenopausal osteoporotic women 52 EVIZON 52 etoposide 52 ribavirin RBV 52 dacarbazine 52 receiving highly emetogenic 52 non splenectomized 52 romiplostim 52 AIR2 Trial 52 intradermal injections 52 darunavir r 52 RoACTEMRA 52 ANCHOR trial 52 Phase III ALLEGRO 52 E1 INT TM 52 PROMUS Element Stent 52 metastatic RCC 52 Pivotal Trial 52 randomized blinded placebo 52 plus methotrexate 52 Randomized Phase 52 atazanavir ritonavir 52 biologic therapy 52 RezularTM 52 aromatase inhibitor therapy 52 GP IIb IIIa inhibitor 52 peginterferon alfa 2a 52 VICTOR E1 52 tesmilifene 52 thetreatment 52 romidepsin 52 Phenoptin 52 non squamous histology 52 partial onset seizures 52 #mg dose [001] 52 huN# DM1 52 custirsen 52 Pivotal Phase III 52 GetGoal Phase III 52 EchoCRT 52 chlorambucil 52 peginterferon alfa 2b 52 OLYMPIA registry 52 μg kg 52 neoadjuvant chemotherapy 52 pharmacokinetic studies 52 carboplatin paclitaxel 52 retrospective cohort 52 paclitaxel Taxol ® 52 metastatic bladder 52 mcg kg 52 RELOVAIR ™ 52 EMPHASIS HF 52 NATRECOR ® 52 ABCSG 52 Androxal TM 52 ADAGIO study 52 ATACAND 52 miconazole Lauriad ® 52 Phase IIb III 52 randomized multicenter Phase III 52 confirmatory Phase III 52 methotrexate monotherapy 52 flutamide 52 beclomethasone dipropionate 52 adult chronic ITP 52 ceftazidime 52 temozolomide 52 everolimus eluting stent 52 evaluable 52 omega interferon 52 randomized placebo controlled 52 relapsed MCL 52 multicenter randomized Phase 52 Lucentis monotherapy 52 #:# randomization 52 mitoxantrone 52 Phase IIb IIIa 52 Acute Coronary Syndromes ACS 52 tolvaptan 52 concomitant medications 52 MIVI III 52 acyclovir Lauriad R 52 clodronate 52 FOLFIRINOX 52 subcutaneously administered 52 blind placebo 52 XIENCE V demonstrated 52 paclitaxel carboplatin 52 de novo kidney transplant 52 non valvular atrial 52 SCIg 52 Subgroup analyzes 52 NLX P# 52 biochemical relapse 52 RECIST criteria 52 ug dose 52 label multicenter Phase 52 oral rivaroxaban 52 efavirenz EFV 52 chemoradiation 52 weekly subcutaneous injections 52 platinum refractory 52 goserelin 52 TAXUS V 52 PFO migraine 52 ARDIS 52 visilizumab 52 Controlled Trial 52 #mg/m# [002] 52 tamibarotene 52 RRMS patients 52 Phase Ia 52 Ophena TM 52 tenofovir emtricitabine 52 pimecrolimus cream 52 retrospectively analyzed 51 corticosteroid dexamethasone 51 Taxus Stent 51 masked placebo controlled 51 vinorelbine 51 CYPHER Stent 51 underwent liver transplantation 51 weekly intravenous infusions 51 Denufosol 51 knee osteoarthritis OA 51 Degarelix 51 Prospective Randomized 51 vismodegib 51 vicriviroc 51 catheter occlusion 51 paclitaxel eluting stents 51 mg BID 51 Kepivance 51 immune modulating 51 undergone radical prostatectomy 51 microgram kg 51 erlotinib Tarceva ® 51 ENESTnd 51 SYMMETRY trial 51 nadolol 51 Efficacy Results 51 ACR# response 51 CTAP# Capsules 51 placebo controlled clinical trials 51 aprepitant 51 Trandolapril 51 controlled multicenter 51 SEROQUEL 51 divalproex sodium 51 IMA# 51 rosuvastatin #mg 51 Phase 1a 51 rALLy clinical trial 51 Free Survival PFS 51 phase 2a 51 timepoints 51 CAMMS# 51 ALN VSP Phase 51 refractory indolent non 51 nondiabetic patients 51 ZYBRESTAT fosbretabulin 51 interferon alfa 51 cisplatin gemcitabine 51 ThermoDox R 51 plus prednisone 51 Phase 2b kidney transplant 51 tenecteplase 51 sirolimus eluting stent 51 sirolimus eluting stents 51 placebo PBO 51 #mg QD [002] 51 HBeAg seroconversion 51 randomized multicentre 51 canakinumab 51 mesalamine granules 51 pediatric acute lymphoblastic 51 oral diclofenac 51 neurologic progression 51 fluticasone furoate 51 label dose titration 51 Arikace 51 low dose Iluvien 51 blinded randomized 51 Telintra 51 blinded placebo controlled 51 dose cytarabine 51 achieving PASI 51 octreotide 51 EORTC 51 aripiprazole Abilify 51 interferon beta 1b 51 Protelos 51 Phase Ib IIa 51 seliciclib 51 Ozarelix 51 external beam radiotherapy 51 label dose escalation 51 prospective observational cohort 51 Double Blind Randomized 51 Kaplan Meier analysis 51 Enzastaurin 51 nonrandomized 51 FOLFIRI 51 dose melphalan 51 placebo intravenously 51 beta2 agonist 51 NP2 Enkephalin 51 Randomised 51 pegylated interferon alfa 2a 51 TTF Therapy 51 ROCKET AF 51 PARTNER Trial 51 relapsed ovarian cancer 51 plus dexamethasone 51 mcg albinterferon alfa 2b 51 randomized 51 Peg IFN 51 MERLIN TIMI 51 hyperphenylalaninemia HPA due 51 pivotal Phase III 51 rt PA 51 peg interferon 51 oxymorphone ER 51 prospective randomized 51 mycophenolate mofetil 51 6R BH4 51 bortezomib Velcade R 51 hepatic encephalopathy HE 51 Pivotal Study 51 Radiation Therapy Oncology 51 eculizumab therapy 51 PF # [001] 51 sitagliptin 51 monotherapy 51 aripiprazole 51 Ceplene/IL-2 51 heavily pretreated patients 51 cytarabine 51 COMFORT II 51 refractory prostate cancer 51 multicenter randomized double 51 NEVO 51 ABVD 51 epirubicin cyclophosphamide 51 SYNTAX trial 51 noninferior 51 XIENCE V PROMUS Stent 51 HeFH 51 gemcitabine Gemzar 51 blind randomized controlled 51 partial remissions 51 HCV infected 51 previously untreated follicular 51 Phase 2a Study 51 LHRH agonist 51 Phase III pivotal 51 complement inhibitor eculizumab 51 follicular NHL 51 Pivotal Phase 51 melphalan prednisone 51 Torisel 51 lintuzumab SGN 51 PEGylated interferon beta 1a 51 cisplatin vinorelbine 51 rimonabant #mg 51 blind randomized placebo 51 dextromethorphan quinidine 51 teduglutide 51 Phase 2b 51 q8h 51 splenectomized patients 51 doxorubicin cyclophosphamide 51 nitazoxanide 51 Systemic Sclerosis 51 ToGA 51 PREZISTA r 51 Anturol TM 51 Clinical Antipsychotic Trials 51 genotypic resistance 51 Phase 2b randomized 51 Teriflunomide 51 olmesartan 51 timepoint 51 hemodialysis patients 51 ZYBRESTAT 51 placebo controlled trials 51 PEG PAL 51 LHRH agonists 51 SCENESSE ® 51 MIRCERA 51 factorial design 51 TAXOTERE R 51 DAPT Study 51 EXPAREL TM 51 paricalcitol 51 LIALDA 51 receiving INTRON 51 PROPEL trial 51 fallopian tube carcinoma 51 CRESTOR #mg 51 EMPHASIS HF trial 51 androgen suppression 51 fallopian tube cancers 51 Gleevec resistant 50 opioid induced bowel dysfunction 50 Cladribine tablets 50 FIRMAGON 50 ibandronate 50 prospectively defined 50 SWOG 50 ARIXTRA 50 Phase III multicenter 50 Percutaneous Coronary Intervention 50 AA Amyloidosis 50 urothelial bladder cancer 50 Phase 2b clinical 50 randomized controlled 50 JAK inhibitor 50 Lodotra TM 50 PNH patients 50 q#h 50 NO# [002] 50 PERSEUS 50 Dose escalation 50 zoledronic acid 50 systemic ALCL 50 Proellex TM 50 #mg doses [002] 50 CombAT 50 maximally tolerated dose 50 TAXUS TM 50 tolterodine 50 Initiate Phase 50 huC# DM4 50 ALVESCO 50 PreCISe 50 Omacetaxine mepesuccinate 50 thymalfasin 50 PRIMO CABG 50 diagnosed Ph + 50 antithymocyte globulin 50 BARI 2D 50 PEGPH# 50 sorafenib Nexavar ® 50 bolus dose 50 unstable angina UA 50 myeloablative therapy 50 mg/m2/day 50 cetrorelix 50 HCV genotype 50 adjuvant radiotherapy 50 sorafenib 50 OPT CHF 50 investigational antiplatelet agent 50 daunorubicin 50 peritumoral brain edema 50 EmbraceAC 50 Peginterferon alfa 2b 50 atherogenic dyslipidemia 50 diagnosed multiple myeloma 50 HGS ETR1 50 demonstrated clinically meaningful 50 Angiox R 50 antiretroviral naive 50 certolizumab pegol 50 recurrent metastatic 50 pharmacodynamic profile 50 VELCADE melphalan 50 Raptiva r 50 5-FU/LV 50 Subgroup analysis 50 afatinib 50 metastatic renal cell 50 CML CP 50 Pharmacokinetics PK 50 Taxotere ® 50 RE LY trial 50 decitabine 50 unresectable stage 50 prospectively enrolled 50 remission CR 50 NEVO RES 50 SJIA 50 recurrent glioma 50 telaprevir dosed 50 rapid virological response 50 dexamethasone Decadron 50 insulin glargine 50 dyslipidaemia 50 mg qd 50 squamous histology 50 analgesic efficacy 50 placebo controlled 50 histologies 50 arsenic trioxide ATO 50 EDEMA3 50 pCR 50 CRLX# 50 adriamycin 50 Aplidin R 50 Advagraf 50 sustained virologic response 50 vidofludimus 50 AVADO 50 relapsed AML 50 FluCAM 50 tiotropium 50 ritonavir boosted lopinavir 50 AzaSite Plus 50 Phase 1b dose escalation 50 pharmacodynamics 50 confirmatory clinical 50 ILUVIEN ® 50 AEG# 50 NCT# ClinicalTrials.gov 50 #mg BID [002] 50 Navelbine 50 trabedersen 50 subcutaneous SC 50 lipid lowering therapy 50 PRE SURGE 50 Randomized Double Blind Placebo 50 bepotastine besilate nasal spray 50 opioid analgesia 50 Multiple Ascending Dose 50 clinically meaningful improvement 50 lacosamide 50 KRN# 50 ENDEAVOR III 50 fibrinolysis 50 virological response 50 KRAS mutant tumors 50 randomized controlled clinical 50 DMARD 50 risperidone Risperdal 50 XL# SAR# 50 NMIBC 50 median PFS 50 free survival PFS 50 liver transplant recipients 50 mixed dyslipidemia 50 AVERROES 50 oral FTY# 50 Complete Response CR 50 longitudinal cohort study 50 mcg dose 50 European Sepsis Trial 50 epirubicin 50 direct thrombin inhibitor 50 patients undergoing percutaneous 50 VADT 50 elagolix 50 STELARA 50 Intervention Trial 50 pharmacodynamic effects 50 bicifadine 50 oral COTI 50 bolus injection 50 pamidronate 50 haematologic 50 chronic lymphocytic leukemia CLL 50 mRCC 50 orphan designation 50 Phase IIb 50 intravitreal insert 50 novel VDA molecule 50 debulking surgery 50 randomized crossover 50 ELONVA 50 Flu Cy 50 5FU 50 fluorouracil 50 lubiprostone 50 Hsp# Inhibitor 50 Phase III Clinical Trial 50 DLTs 50 subgroup analyzes